JP7792395B2 - 抗クローディン１８．２多重特異性抗体及びそれらの使用 - Google Patents

抗クローディン１８．２多重特異性抗体及びそれらの使用

Info

Publication number
JP7792395B2
JP7792395B2 JP2023507973A JP2023507973A JP7792395B2 JP 7792395 B2 JP7792395 B2 JP 7792395B2 JP 2023507973 A JP2023507973 A JP 2023507973A JP 2023507973 A JP2023507973 A JP 2023507973A JP 7792395 B2 JP7792395 B2 JP 7792395B2
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023507973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537002A5 (enExample
JP2023537002A (ja
Inventor
ガン アン，
ズーシェン リー，
ユアン リウ，
アダム ペルゼック，
ショーン マーフィー，
ルーシー ジャン，
シェンチン ワン，
ヤンデ チェン，
マルコ ムダ，
ジェイムズ ルロ，
ウェイ リー，
Original Assignee
アブプロ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブプロ コーポレーション filed Critical アブプロ コーポレーション
Publication of JP2023537002A publication Critical patent/JP2023537002A/ja
Publication of JP2023537002A5 publication Critical patent/JP2023537002A5/ja
Priority to JP2025250936A priority Critical patent/JP2026034608A/ja
Application granted granted Critical
Publication of JP7792395B2 publication Critical patent/JP7792395B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023507973A 2020-08-06 2021-08-05 抗クローディン１８．２多重特異性抗体及びそれらの使用 Active JP7792395B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025250936A JP2026034608A (ja) 2020-08-06 2025-12-15 抗クローディン１８．２多重特異性抗体及びそれらの使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063061895P 2020-08-06 2020-08-06
US63/061,895 2020-08-06
US202063074582P 2020-09-04 2020-09-04
US63/074,582 2020-09-04
US202163144657P 2021-02-02 2021-02-02
US63/144,657 2021-02-02
PCT/US2021/044801 WO2022032004A2 (en) 2020-08-06 2021-08-05 Anti-claudin 18.2 multi-specific antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025250936A Division JP2026034608A (ja) 2020-08-06 2025-12-15 抗クローディン１８．２多重特異性抗体及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2023537002A JP2023537002A (ja) 2023-08-30
JP2023537002A5 JP2023537002A5 (enExample) 2024-08-13
JP7792395B2 true JP7792395B2 (ja) 2025-12-25

Family

ID=80117669

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023507973A Active JP7792395B2 (ja) 2020-08-06 2021-08-05 抗クローディン１８．２多重特異性抗体及びそれらの使用
JP2025250936A Pending JP2026034608A (ja) 2020-08-06 2025-12-15 抗クローディン１８．２多重特異性抗体及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025250936A Pending JP2026034608A (ja) 2020-08-06 2025-12-15 抗クローディン１８．２多重特異性抗体及びそれらの使用

Country Status (5)

Country Link
US (1) US20230279152A1 (enExample)
EP (1) EP4192879A4 (enExample)
JP (2) JP7792395B2 (enExample)
KR (1) KR20230070203A (enExample)
WO (2) WO2022032004A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20250158109A1 (en) 2022-05-31 2025-05-15 Lg Energy Solution, Ltd. Composite solid electrolyte for lithium secondary battery and preparation method thereof
CN119101162A (zh) * 2023-06-07 2024-12-10 江苏奥赛康生物医药有限公司 一种抗cldn18_2的抗体及体外诊断试剂盒
WO2024250437A1 (en) * 2023-06-08 2024-12-12 Antengene (Hangzhou) Biologics Co., Ltd. Anti-cldn18.2 antibodies and diagnostic uses thereof
CN119874911B (zh) * 2025-01-02 2025-12-30 上海以岭药业有限公司 靶向cldn18.2的抗原结合蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019242505A1 (zh) 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
JP2020018298A (ja) 2018-08-03 2020-02-06 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
WO2016054598A2 (en) * 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
EP3302563A1 (en) * 2015-05-29 2018-04-11 H. Hoffnabb-La Roche Ag Humanized anti-ebola virus glycoprotein antibodies and methods of use
CA2990398A1 (en) * 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-cd123-antibodies
CN116178554B (zh) * 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
WO2020023679A1 (en) * 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
US10522488B1 (en) * 2018-10-31 2019-12-31 Taiwan Semiconductor Manufacturing Company, Ltd. Patterning polymer layer to reduce stress
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019242505A1 (zh) 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
JP2020018298A (ja) 2018-08-03 2020-02-06 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト

Also Published As

Publication number Publication date
WO2022032003A3 (en) 2022-04-07
WO2022032003A2 (en) 2022-02-10
EP4192879A2 (en) 2023-06-14
EP4192879A4 (en) 2024-12-04
WO2022032004A3 (en) 2022-03-17
US20230279152A1 (en) 2023-09-07
JP2023537002A (ja) 2023-08-30
WO2022032004A2 (en) 2022-02-10
KR20230070203A (ko) 2023-05-22
JP2026034608A (ja) 2026-02-27

Similar Documents

Publication Publication Date Title
JP2026034608A (ja) 抗クローディン１８．２多重特異性抗体及びそれらの使用
US12486323B2 (en) Anti-L1-CAM antibodies and uses thereof
JP7730295B2 (ja) Ｃｄ１９抗体およびこれを使用する方法
US20240327511A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
JP7805287B2 (ja) 抗ｓｔｅａｐ１抗体およびその使用
JP7598324B2 (ja) Ｃｄ３３抗体とそれを用いた癌を治療する方法
JP7788859B2 (ja) がんを処置するための抗ｃｄ３３抗体
US20250340637A1 (en) Cd3 targeting antibodies and uses thereof
JP7386800B2 (ja) 抗ポリシアル酸抗体およびその使用
US20240026037A1 (en) Anti-gpa33 multi-specific antibodies and uses thereof
CN116529264A (zh) 抗claudin 18.2多特异性抗体及其用途
AU2024344464A1 (en) Gpa33 antibody compositions and uses thereof
US20230374150A1 (en) Anti-psma antibodies and uses thereof
JP2024531913A (ja) 抗ｈｅｒ２抗体及びそれらの使用
HK40097926A (en) Anti-claudin 18.2 multi-specific antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251215

R150 Certificate of patent or registration of utility model

Ref document number: 7792395

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150